Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Letolizumab by Bristol-Myers Squibb for Graft Versus Host Disease (GVHD): Likelihood of Approval
Letolizumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Graft Versus Host Disease (GVHD). According...